Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
159K
-
Shares change
-
+38.8K
-
Total reported value, excl. options
-
$2.41M
-
Value change
-
+$587K
-
Number of buys
-
1
-
Price
-
$15.37
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q4 2023
2 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q4 2023.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 159K shares
of 72.2M outstanding shares and own 0.22% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), EVENTIDE ASSET MANAGEMENT, LLC (11.6M shares), FMR LLC (10.3M shares), VANGUARD GROUP INC (5.35M shares), BlackRock Inc. (4.68M shares), STATE STREET CORP (4.42M shares), CITADEL ADVISORS LLC (3.68M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.9M shares), Capital International Investors (2.82M shares), and T. Rowe Price Investment Management, Inc. (2.34M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.